Drug Discovery World

AUGUST 16, 2023

Samir Ounzain , PhD, CEO & Co-Founder of HAYA Therapeutics, looks at how a better understanding of our DNA can lead to increased activity for RNA therapeutics. The whole world realised the power of RNA when the Covid-19 pandemic brought us the first mRNA-based vaccines.

RNA 52

RNA Genome Genomics DNA 52

Pharmaceutical Technology

FEBRUARY 9, 2023

The collaboration is aimed at discovering and developing new advanced treatments for genitourinary (GU) tumours as well as other related serious diseases using ReviR’s RNA-targeted technologies. ReviR combines computational and high throughput drug discovery technologies to deliver advanced medicines to patients.

Development 241

Development RNA Gene Therapy Genetics 241

Drug Discovery World

MAY 21, 2024

Takara Bio has launched PrimeCap T7 RNA Polymerase (low dsRNA), a mutant T7 RNA polymerase suitable for mRNA therapeutic research and development. Further genetic modifications have resulted in a four-fold reduction of cap analogue concentration in the IVT reaction whilst maintaining a capping efficiency above 95%, said the company.

Production 59

Production RNA In-Vitro Genetic Engineering 59

Drug Discovery World

AUGUST 16, 2023

A new study has shed light on the genetic messages encoded by genes within ‘triple negative’ breast cancers (TNBC), and shows they could predict response to chemotherapy. Although immune features remained relatively stable, RNA-based features related to DNA damage repair pathways changed significantly.

Genetics 52

Genetics Gene Hormones RNA 52

pharmaphorum

MAY 14, 2021

Biogen has made a further push into RNA-based drug discovery via a collaboration with Envisagenics, which applies artificial intelligence RNA sequencing data to discover new drug targets and therapeutics. At least 370 genetic disorders are known to derive from errors introduced during this splicing process.

RNA 60

RNA Licensing Licensing Genetics 60

Scienmag

JULY 2, 2021

Studies using human cell lines and tumors grown in mice provide early evidence that inhibiting RNA-binding proteins, a previously overlooked family of molecules, might provide a new approach for treating some cancers Credit: UC San Diego Health Sciences In cancer research, it’s a common goal to find something about cancer cells — some sort (..)

RNA 87

RNA Protein Drugs Research 87

Drug Discovery World

NOVEMBER 17, 2022

The study is the first to use transcriptomics as a blood test to measure RNA levels in patients with long-term Lyme disease. . As part of the study, RNA sequencing was conducted using blood samples from 152 patients with symptoms of post-treatment Lyme disease to measure their immune response. .

Genetics 52

Genetics RNA Immune Response Bioinformatics 52

Drug Discovery World

MARCH 7, 2024

Ginkgo Bioworks has acquired Patch Biosciences, with the intention to strengthen its gene therapy services, cell therapy services, and RNA therapeutics services. JB Michel, CEO and co-founder of Patch Biosciences: “Joining Ginkgo Bioworks represents an exciting step in our journey to engineer better genetic medicines.

Gene Therapy 52

Gene Therapy RNA Engineer Gene 52

STAT News

JANUARY 25, 2023

From Covid-19 vaccines to therapies against a range of deadly diseases, every RNA molecule has a complex 3D shape that controls its function. But the startup already has big ambitions for how its AI-based approach can both help biotechs identify RNA-targeting drugs and design RNA to be stable, compact, or to have other desired properties.

RNA 52

RNA Vaccination Vaccine Development 52

Drug Discovery World

MAY 17, 2024

From a weight loss drug that prevents heart attacks and a gene therapy that restores hearing, to a vaccine that can treat viruses that don’t exist yet, our chosen news stories this week all represent potential breakthroughs in their respective fields. News round-up for 13-16 May by DDW Senior Digital Content Editor Diana Spencer.

Gene Therapy 52

Gene Therapy Gene Drugs In-Vivo 52

Camargo

JULY 27, 2021

When developing a clinical development program for these increasingly popular therapies, it is important that sponsors use modeling and pharmacokinetic (PK) analysis to evaluate parameters that can be measured while dosing with gene therapy drugs, to characterize exposure-response data and inform rational dosing. Gene Therapy Definition.

Gene Therapy 238

Gene Therapy Gene Gene Editing Genetics 238

Drug Discovery World

MARCH 21, 2024

A project focused on developing a small RNA-based platform technology for treating monogenic diseases, smartRNA, has joined the BioInnovation Institute’s (BII) Bio Studio programme. The technology has platform potential, as it leverages a universal small RNA pathway to target generic mRNA features.

RNA 52

RNA Protein Engineer Business Development 52

XTalks

JUNE 20, 2022

Alnylam Pharmaceuticals, a leading RNA interference (RNAi) therapeutics biopharmaceutical company, announced it received approval from the US Food and Drug Administration (FDA) for its RNAi therapeutic Amvuttra (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (ATTR) amyloidosis in adults.

FDA Approval 98

FDA Approval Protein Genetics RNA 98

Drug Discovery World

FEBRUARY 13, 2023

Dr Stephen Barat, Senior Vice President and Therapeutics Division Head at HTG Molecular Diagnostics tells DDW how transcriptomics is driving drug discovery and precision medicines. SB: Transcriptomics is the study of genomic RNA transcripts in a biological system. DDW: Could you explain the process of transcriptomics?

RNA 52

RNA Drugs Gene Expression Gene 52

Pharmaceutical Technology

JANUARY 12, 2023

Under the research partnership deal, the companies will develop new precision genetic medicines for a severe form of genetic dilated cardiomyopathy (DCM). We believe the advanced RNA technology and human disease models of Phlox Therapeutics perfectly partner with the delivery tools Solid Biosciences brings to this collaboration.”.

RNA 130

RNA Gene Therapy Genetics Genetic Disease 130

pharmaphorum

OCTOBER 5, 2022

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule. billion deal in 2018.

RNA 105

RNA Genetics Dermatology Antibody 105

pharmaphorum

JANUARY 26, 2023

We are already seeing an increase in projects exploring population genomics in Africa, the Middle East, and Asia, with initiatives including the GenomeAsia100K Project and the Genome Aggregation Database focusing on capturing genetic data of non-European individuals. Just one mutation can lead to a complete change in protein formation.

Genome 130

Genome Genomics Genome Project Genetics 130

The Pharma Data

AUGUST 16, 2021

The antiviral agent incorporates RNA-like building blocks into the RNA genome of the virus. If this genetic material is further replicated, defective RNA copies are produced and the pathogen can no longer spread. Molnupiravir, another antiviral drug candidate, was originally developed to treat influenza.

RNA 52

RNA Drugs Genome Genomics 52

Roots Analysis

FEBRUARY 23, 2022

Further, NGS library preparation kits offer several benefits, such as low requirement of starting material, generation of longer RNA / DNA sequences and production of superior quality nucleotide libraries, thereby, catering to existing unmet needs of the research domain. Next Generation Sequencing (NGS) Library Preparation Kits. Web: [link].

Genetics 52

Genetics DNA RNA Reagent 52

Drug Discovery World

APRIL 17, 2024

DDW’s Diana Spencer speaks to Josh Mandel-Brehm , CEO of Massachusetts-based biotech CAMP4, to understand the role regulatory RNAs play in gene expression and how the founders overcame the challenge of launching a business based on brand new science. What are the challenges of drug discovery in this area? How do they work?

Gene Expression 59

Gene Expression Gene Genetic Disease RNA 59

Drug Discovery World

APRIL 4, 2023

Can NGS increase the chances of an oncology drug making it to market? Can NGS identify previously undruggable targets in cancer? How can the technology best be implemented in research labs? Will NGS help drive personalised cancer therapies? Can NGS technology help direct patients towards suitable clinical trials? Register now.

Drugs 52

Drugs RNA Genome Genomics 52

Drug Discovery World

MARCH 2, 2023

A new paper has solved the 20-year mystery of how epigenetic modifications act as traffic lights to control gene expression and could ultimately speed up the development of a new class of epigenetic cancer drugs. When it gives the green light, H3K4me3 allows RNA polymerase II to move along DNA, transcribing it into RNA as it moves.

Gene Expression 52

Gene Expression Gene DNA RNA 52

Drug Discovery World

APRIL 3, 2023

Hosted by DDW and supported by Tecan, “How next-generation sequencing is informing oncology drug discovery” will be free to attend on April 24 at 7AM PST / 10AM EST / 3PM BST / 4PM CET. Join this free webinar to learn about the biggest challenges and opportunities facing the NGS oncology space. You will hear from Darrell Green, a lecturer in (..)

RNA 52

RNA Drugs Genome Genomics 52

Drug Discovery World

APRIL 24, 2023

Can NGS increase the chances of an oncology drug making it to market? Can NGS identify previously undruggable targets in cancer? How can the technology best be implemented in research labs? Will NGS help drive personalised cancer therapies? Can NGS technology help direct patients towards suitable clinical trials? Register now.

RNA 52

RNA Drugs Genome Genomics 52

Roots Analysis

OCTOBER 13, 2023

Over the last two decades the pharmaceutical industry has observed a paradigm shift from conventional drug delivery strategies to more enhanced, potent, and targeted therapeutics. This led the researchers to find alternative pathways and drug delivery strategies to enhance the potent delivery of the drug to the site of action.

Drugs 40

Drugs Antibody RNA Genetics 40

Drug Discovery World

APRIL 11, 2023

Can NGS increase the chances of an oncology drug making it to market? Can NGS identify previously undruggable targets in cancer? How can the technology best be implemented in research labs? Will NGS help drive personalised cancer therapies? Can NGS technology help direct patients towards suitable clinical trials? Register now.

RNA 52

RNA Drugs Genome Genomics 52

Drug Discovery World

APRIL 18, 2023

Can NGS increase the chances of an oncology drug making it to market? Can NGS identify previously undruggable targets in cancer? How can the technology best be implemented in research labs? Will NGS help drive personalised cancer therapies? Can NGS technology help direct patients towards suitable clinical trials? Register now.

RNA 52

RNA Drugs Genome Genomics 52

Scienmag

SEPTEMBER 30, 2020

Scientists are fighting back with multiple strategies, including vaccines, repurposed drugs developed for other diseases and brand-new therapies. Now, researchers reporting in ACS Central Science have identified small molecules that target a structure within the RNA genome […].

RNA 40

RNA Genome Genomics Branding 40

Scienmag

FEBRUARY 3, 2022

In a Perspective, Ronald Swanstrom and Raymond Schinazi argue that antiviral drugs that lead RNA viruses to produce genetic mutations so fast that they cannot remove deleterious ones – a strategy used in antivirals like the recently approved COVID-19 drug molnupiravir – may be viable, but also present unknown risks to the host.

RNA 66

RNA Genetics Drugs 66

Delveinsight

SEPTEMBER 23, 2021

Boehringer Ingelheim acquires Abexxa Biologics for precision most cancers drug pipeline. 858 Therapeutics closes USD 60 Million series A round to drug RNA modulation. Now, they are ready for their next venture, which is launching RNA biotech 858 Therapeutics with a USD 60 million Series A fundraising. Stafford and co.

RNA 61

RNA Gene Therapy Gene Protein 61

Scienmag

NOVEMBER 20, 2020

Scientists at Goethe University within the international consortium COVID19-NMR refine previous 2D models The genetic code of the SARS-CoV2 virus is exactly 29,902 characters long, strung through a long RNA molecule. It contains the information for the production of 27 proteins.

Genome 70

Genome Genomics RNA Protein 70

Drug Discovery World

SEPTEMBER 27, 2023

Embarking on a new era of medicine The advent of genomics has ushered in the era of personalised medicine, enabling us to analyse the genetic makeup of individuals with unprecedented accuracy. Genetic variations inherited from our parents shape our response to drugs, disease susceptibility, physiology and metabolism.

DNA 115

DNA Genetics Gene Medicine 115

Drug Discovery World

MARCH 21, 2023

Diana Spencer explores the different ways the drug discovery sector is tackling colorectal cancer. So, what are the recent developments and how is the drug discovery sector tackling this common cancer? Improved diagnostics Diagnostics and screening are essential to the early treatment of colorectal cancer.

Drugs 52

Drugs Gene Expression RNA Clinical Trials 52

BioTech 365

NOVEMBER 23, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Folding of SARS-CoV2 genome reveals drug targets—preparation for SARS-CoV3.The The genetic code of the SARS-CoV2 virus is exactly 29,902 characters long, strung through a long RNA molecule.

Genome 40

Genome Genomics RNA Drugs 40

Drug Discovery World

JUNE 22, 2023

“This is part of our long-term business strategy of leveraging exosome-mediated delivery to create and enable genetic medicines such as gene therapy and genome editors”. The post Evox Therapeutics acquires exosome AAV technology from Codiak appeared first on Drug Discovery World (DDW).

Gene Therapy 52

Gene Therapy Gene Editing Drug Delivery Gene 52

Pharmaceutical Technology

DECEMBER 14, 2022

GSK has entered a strategic partnership with Wave Life Sciences to progress the discovery and development of oligonucleotide therapies for new genetic targets. The alliance will merge the PRISM oligonucleotide platform of Wave and the capabilities of GSK in genetics and genomics.

Life Science 162

Life Science Development Gene Therapy Genetics 162

Drug Discovery World

JUNE 9, 2023

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to DTx Pharma’s DTx-1252, an investigational small interfering RNA (siRNA) therapeutic for the treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A). “We are pleased to receive Orphan Drug Designation from the FDA for DTx-1252. .

Genetics 52

Genetics RNA Packaging Packaging 52